Porphyromonas gingivalis, the major causative bacterium of periodontitis, contributes significantly to elevated proteolytic activity at periodontal pockets owing to the presence of both bacteria and host, predominantly neutrophil-derived, serine proteases. Normally the activity of the latter enzymes is tightly regulated by endogenous proteins, including elafin, a potent neutrophil elastase and proteinase 3 inhibitor released from epithelial cells at sites of inflammation. Here, we report that all three gingipains (HRgpA, RgpB, and Kgp) have the ability to degrade elafin, with RgpB being far more efficient than other gingipains. RgpB efficiently inactivates the inhibitory activity of elafin at subnanomolar concentrations through proteolysis limited to the Arg22-Cys23 peptide bond within the surface loop harboring the inhibitor active site. Notably, elafin resists inactivation by several Staphylococcus aureus-derived serine and cysteine proteases, confirming the high stability of this protein against proteolytic degradation. Therefore, we conclude that elafin inactivation by RgpB represents a specific pathogenic adaptation of P. gingivalis to disturb the protease-protease inhibitor balance in the infected gingival tissue. This contributes to enhanced degradation of host proteins and generation of a pool of peptides serving as nutrients for this asaccharolytic pathogen.
Introduction
Periodontitis is the most prevalent inflammatory disease driven by microorganisms inhabiting the subgingival bacterial plaque. Although more than 600 bacterial species were found in this dwelling only a handful are considered pathogenic, including Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola (Kuru et al., 1999) . Out of this trio, P. gingivalis is the best investigated pathogen with regard to virulence traits, which are apparently involved in initiation and maintenance of pathogenic conditions driving chronic inflammation. It is believed that formidable forces of innate immunity frustrated by inability to eradicate irritating infection are directly responsible for periodontal tissues degradation and eventual teeth loss (Oliver and Brown, 1993; Cutler et al., 1995; Haffajee et al., 1998; Socransky et al., 1998) . Cysteine proteases of P. gingivalis, referred to as gingipains, are the major virulence factors manipulating mechanisms of host defenses against infection .
Gingipains are produced by three genes (rgpA, rgpB, and kgp) strictly encoding Arg-Xaa (RgpA and RgpB) and Lys-Xaa (Kgp) peptide bond specific proteases, respectively (Mikolajczyk-Pawlinska et al., 1998) . Owing to post-translational processing and modifications, gingipains are secreted in many different molecular forms, both soluble and associated with the outer membrane of the bacterial surface (Potempa et al., 2003) . Although gingipains can directly degrade components of the connective tissue, they can inflict far more damage by usurping functions of tightly regulated host proteases of coagulation, fibrinolysis, complement, receptor signaling, and kinin-release pathways (Potempa and Pike, 2009) . Moreover, by inactivation of endogenous proteinase inhibitors gingipains can contribute to uncontrolled proteolytic activity at the periodontitis sites infected with P. gingivalis.
One of the hallmarks of periodontitis is infiltration of the periodontal tissue by a large number of neutrophils. Neutrophils, an indispensable arm of innate immunity, can do a lot of collateral damage to the connective tissue if powerful proteases, including human neutrophil elastase (HNE), proteinase 3, and cathepsin G, are released from disintegrated cells. As a countermeasure blood plasma leaking into inflammatory sites (edema) provides high quantities of endogenous inhibitors. Also, some inhibitors are produced locally reinforcing antiproteolytic activity of serum. Among those inhibitors elafin secreted by epithelial cells under proinflammatory stimuli is a reversible inhibitor of neutrophil elastase and proteinase 3 (Wiedow et al., 1990) . The inhibitory potential characterized by K i in a subnanomolar range and high levels of expression (Wiedow et al., 1990; Alkemade et al., 1994; Pfundt et al., 1996; Guyot et al., 2005) makes elafin the major elastase and proteinase 3 inhibiting agent in inflamed epithelial tissues (Alkemade et al., 1994) . Unlike plasma inhibitors susceptible to oxidative and proteolytic Figure 1 Elafin is inactivated by proteases of P. gingivalis but not S. aureus. Elafin was preincubated with a bacterial protease at a 1:1 molar ratio for 2 h at 378C before human neutrophil elastase (HNE) was added (molar ratio of HNE/elafins1:2). Residual elastase activity was determined with MeoSuc-AAPV-pNa as substrate. Presented results are normalized to percentage of the appropriate control. Incubation with P. gingivalis-derived cysteine proteases (HRgpA, RgpB, and Kgp) significantly decreased the inhibitory potential of elafin but only RgpB did not interfere with activity of elastase (B). ZFFRck indicates protease inhibitor Z-PhePhe-Arg-chloromethyloketone. Staphylococcal proteases (ScpA, SspA, SspB, and SplA) did not affect inhibitory activity of elafin.
(B) Influence of tested bacterial proteases on elastase activity is shown. Bars represent the mean of triplicate measurements"SEM. Experiments shown are representative for at least three replicates.
inactivation, elafin with four disulfide bridges stabilizing the reactive center loop is an extremely stable molecule resistant to proteolytic degradation in its native, unreduced form (Alkemade et al., 1994; Guyot et al., 2005) . Nevertheless, enhanced local expression of elafin in the inflamed connective tissue of the periodontium is apparently not sufficient to control neutrophil proteases and gingival crevicular fluid (GCF) contains free elastase activity. Significantly, the level of elastase activity was found to correlate not only with the P. gingivalis infection but also with the presence of Rgps in GCF (Mailhot et al., 1998) . Therefore, our goal was to investigate whether gingipains, in comparison to proteases from Staphylococcus aureus, can interfere with inhibitory activity of elafin and elucidate a mechanism of inhibitor interaction with gingipains.
Results

Specific inactivation of elafin by RgpB
Proteases from P. gingivalis and S. aureus were investigated for their ability to affect elafin-dependent inhibition of HNE. All tested proteases of P. gingivalis had the ability to inactivate elafin but with varying efficiency. Under experimental conditions applied (Figure 1 ), only Argspecific gingipain B (RgpB) inactivated elafin completely with no residual anti-HNE activity of elafin left after 2 h preincubation. This effect was dependent on the proteolytic activity of RgpB as demonstrated by complete preservation of elafin inhibitory capacity when the inhibitor was preincubated with Z-Phe-Phe-Arg-chloromethyloketone-treated RgpB.
HRgpA and Kgp had incremental effect on anti-elastase capacity of elafin diminishing it by 60% and 80%, respectively. Notably, in contrast to RgpB these gingipains directly inactivated HNE to some extent. After preincubation with HRgpA and Kgp, the HNE activity was decreased by 85% and 70%, respectively ( Figure 1B ). Contrary to gingipains none of the tested staphylococcal enzymes affected inhibitory capacity of elafin under the experimental conditions and only glutamyl endopeptidase I (SspA) interacted directly with HNE. However, in comparison to HRgpA and Kgp the effect of SspA was far less profound. After preincubation with SspA, HNE lost only 15% activity ( Figure 1B) .
To further characterize RgpB interaction with elafin, we determined the time-and concentration-dependent effect of RgpB on the elafin inhibitory activity and protein integrity (Figures 2 and 3) . At subnanomolar concentration (0.5 nM) RgpB significantly diminished the elafin anti-HNE activity (Figure 2 ). The total inactivation of the inhibitor occurred within 2 h when elafin was incubated with 5 nM RgpB. Gingipain-exerted elafin inactivation was not correlated with the inhibitor degradation when the integrity of the elafin molecule was assessed using non-reducing SDS-PAGE analysis ( Figure 3A, B) . RgpB up to 50 nM did not cause any significant cleavage of elafin and only at concentrations 100 nM and higher a discrete cleavage product stable for further degradation even at 500 nM RgpB was observed under non-reducing conditions. However, separation of reduced samples ( Figure 3C , D) revealed rapid degradation within 15 min of elafin by 100 nM RgpB. A single cleavage product was observed with an apparent molecular mass of 4.3 kDa. We concluded that elafin is inactivated by RgpB possibly owing to limited proteolysis within a disulfide bridgebound loop of the inhibitor.
To determine the cleavage site(s), elafin was incubated with RgpB and applied to HPLC reverse-phase chromatography ( Figure 4 ). Collected fractions were analyzed by mass spectrometry and tested for elastase inhibition (Table 1) . The HPLC separation after RgpB treatment revealed two major fractions (numbers 2 and 3 in Figure  4B ) eluting shortly before the fraction of residual intact elafin (number 5 in Figure 4B ). A peptide in fraction numbers 2 and 3 exhibited a molecular mass of 6016.5 Da (Table 1) precisely matching the molecular mass of native elafin with intact disulfide bridges and hydroxylation at Figure 2 The gingipain RgpB inactivates elafin in a dosedependent manner. Elafin (10 nM final concentration) was preincubated with increasing concentrations of RgpB and residual elastase inhibitory activity of elafin was determined as described in Figure 1 and is shown as remaining percentage of inhibition in relation to elastase activity alone. Inactivation of elafin was previously observed at subnanomolar concentrations of RgpB. Bars represent mean of triplicate measurements"SEM. The experiment shown is representative for at least three replicates. ***Significant difference in relation to 0 nM RgpB using Student's t-test, p-0.05. (A) Elafin (1 mg) was incubated with the indicated final concentration of RgpB for 2 h and the samples were subjected to SDS-PAGE. (B) Elafin (10 mg) was incubated with RgpB (100 nM) and at specific time points 10 ml aliquots were withdrawn, mixed with the sample buffer (SB), and instantly frozen. All collected samples were resolved using 15.5:1 T/C, 15% SDS-PAGE in non-reducing conditions. (B, C) Samples were prepared similarly, mixed with sample buffer with DTT, and boiled for 5 min. Reduced samples were separated using peptide gel (16% acrylamide, T/C 8.5:1). Protein bands were stained with silver. M, molecular mass marker. one single amino group position. This form of elafin exhibited no inhibitory activity even at five molar excess over elastase. Hydroxylation and loss of inhibitory activity of elafin did not occur spontaneously as shown in control experiments ( Figure 4A , Table 1 ). In addition to the major cleaved product, a minor one was identified in fraction 4 ( Figure 4B ). This fraction constitutes 7.6% of the starting elafin and contains an inhibitory inactive peptide with a molecular mass of 5364.6 Da matching that of the major form of proteolytically modified elafin additionally truncated at Lys6. This cleavage site is rather unusual for Arg-specific RgpB; however, as our proteases were purified from native bacteria, a trace contamination of our enzyme preparation with Kgp (Lys-specific gingipain) is possible.
Non-reducing SDS-PAGE (data not shown) and Western blot analysis ( Figure 4C ) of HPLC resolved elafinderived peptides revealed bands with the same mobility as the intact elafin with the notable exception of the Nterminally truncated elafin in fraction no. 4. However, SDS-PAGE resolution of elafin and elafin degradation products under reducing conditions discriminated the intact and the cleaved inhibitor ( Figure 3C, D) . This finding confirms that elfin with a single peptide bond cleaved is inactive as the elastase inhibitor, despite the stable structure maintained by disulfide bridges.
RgpB is known to exclusively cleave the arginine-Xaa peptide bond. To determine which of the two Arg-Xaa peptide bonds present in the elafin polypeptide chain is cleaved, fractions of RgpB-treated elafin (fraction numbers 2, 3, and 4 in Table 1 ) were reduced with dithiothreitol (DTT) and subsequently alkylated. Samples were subjected again to reverse-phase HPLC and the resulting fractions were analyzed by mass spectrometry. The observed masses of RgpB-generated peptides in fraction numbers 2 and 3 matched the molecular mass of the elafin fragments derived from cleavage at the Arg22-Cys23 peptide bond (Table 2) corresponding to the apparent molecular mass of the cleavage product identified in the reducing SDS-PAGE. By contrast, the peptide in fraction number 4 corresponded to Arg22-hydrolyzed elafin, N-terminally truncated at Lys6. Notably, no elafin fragments indicating a cleavage at Arg31 were detected.
Discussion
Elafin is a very potent inhibitor of the neutrophil serine proteases elastase and proteinase 3. The structure of On all other lanes, the visible band has the same mobility as intact elafin. Some differences are observed in antibody affinity, as bands 2, 3, and 4 are noticeably weaker than controls (5, 6), despite the fact that all lanes were loaded with the same protein amount. Figure  4 . Protein amount was calculated by area under peak from indicated fraction. Elafin (10 mg) was initially applied on RP-HPLC. Molecular masses were determined by ESI-MS analyses and elastase inhibition by a 5-molar excess of elafin fraction compared to HNE. Fraction numbers are the same as in Table 1 . Fractions were reduced, alkylated, and separated by HPLC. Resulting fractions were measure by ESI-MS. Calculated molecular masses of reduced and alkylated cleavage products of elafin are given. Elafin product describes the amino acid position of the correlating theoretical molecular mass.
elafin consists of a single four-disulfide core protein domain, with the reactive site loop expanding to the outside. The rigid, strongly stabilized core renders elafin unusually stable and resistant to proteolysis (Guyot et al., 2005) , which is considered as an adaption to function in a proteolytic milieu. Elafin expression is induced in inflamed epithelial tissues playing an important role in the regulation of elastase and proteinase 3 activities at sites of inflammation. In addition to having tissue destructive activity, neutrophil serine proteases have the ability to promote inflammation by processing proinflammatory cytokines and activating various inflammatory receptors (Wiedow and Meyer-Hoffert, 2005; MeyerHoffert, 2009 ). Uncontrolled neutrophil protease activity results in enhanced local inflammation and tissue destruction providing peptides which are indispensable nutrients for asaccharolytic P. gingivalis. Although P. gingivalis proteases, including gingipains, can directly degrade many host proteins, here we show that peptidic nutrients generation can be accomplished in a more efficient indirect way. As high elastase and proteinase 3 activities were reported in GCF (Cox and Eley, 1989; Uitto et al., 2003) , we presumed that P. gingivalis can interfere with control mechanisms of proteolysis in the periodontal tissue utilizing the host inflammatory proteases elastase and proteinase 3 to facilitate local overall proteolytic activity. We describe herein proteolytic inactivation of elafin by the gingipain RgpB and propose a potential novel virulence trait for this bacterial enzyme. Compared to other proteases from P. gingivalis and S. aureus, this inactivation was highly specific and efficient. Although we could detect some proteolytic inactivation of elastase activity by HRgpA and Kgp, this partial inactivation might be of low relevance in the in vivo situation because overall elastase activity is elevated in GCF (Cox and Eley, 1989) . In the gingival pocket, elafin might be exposed to (Tsunemi et al., 1996) . 3-D images were prepared with Python Molecular Viewer (Sanner, 1999) .
both elastase and RgpB simultaneously. Preliminary experiments suggest that RgpB does not have the ability to cleave elafin efficiently in complex with elastase (data not shown). However, local concentration of elafin is probably higher than those of HNE in the gingival pocket. Under these conditions RgpB might cleave free elafin. Moreover, as other gingipains are efficient in inactivation of HNE, the HNE-elafin complex might be destroyed in order to release free elafin, now accessible to RgpBmediated cleavage. Importantly, it must be considered that high concentrations of elastase substrates such as elastin compete with each other and elastase inhibitors in the in vivo situation. Moreover, pre-elafin (trappin-2) might be covalently bound via transglutamination to extracellular proteins, including laminin, fibronectin, fibrinogen, and elastin. Elafin as well as its proform remain potent inhibitors of HNE and proteinase 3 and various authors have proposed that such anchoring might provide a local protection from excessive proteolysis by neutrophil proteinases. Whether pre-elafin is inactivated by RgpB needs further experimental confirmation. HPLC separation of the RgpB/elafin mixture revealed three distinct cleavage products with no elastase inhibitory activity. As two cleavage products were expected for each of the two arginine residues of the elafin amino acid sequence, the presence of the third was surprising and was later deciphered as additional cleavage after Lys6. Most interestingly, both dominant HPLC peaks contained elafin inactivated by hydrolysis after Arg22, which were possibly separated on the basis of slight structural differences occurring after cleavage. Hydrolysis after the Arg22 residue might result in the formation of two distinct folds of the loop region. Analysis of the elafin structure in the complex with porcine pancreatic elastase revealed a complex structural organization of the expanded reactive site loop (RSL) (Tsunemi et al., 1996) . The RSL, expanding from Leu20 to Leu26, is covalently attached to the rigid core region of the molecule by the disulfide bond between Cys23 and Cys49; however, this bond takes an unusual, expanded conformation ( Figure 5 ). As revealed by solution NMR experiments (Francart et al., 1997) , this extended conformation is enforced by two Pro28 and Pro29 residues, which provide a rigid scaffold for the expanding loop. This fold is further supported by a network of hydrogen bonds. Two h-amino groups of Arg22, P3 residue, according to the Schechter and Berger nomenclature (Schechter and Berger, 1967) , form hydrogen bonds with the P19 Met25. Furthermore, Cys22 forms a hydrogen bond with Ser48, additionally stabilizing the fold of RSL. The observed cleavage by RgpB breaks up this network by reformatting the carboxyl group of Arg22. This can lead to the destruction of hydrogen bonds between Arg22 and Met25, leaving this region unstable. Subsequently, this event might lead to lower interaction in the P2-P39 fragment of RSL, which can lead to the restoration of optimal conformation of the Cys23-Cys45 disulfide bridge and possibly might result in the collapse of this fragment into the core region and to the inactivation of the protease inhibitory activity. Single hydrolysis inactivation of elafin at nanomolar levels of RgpB concentration can be interpreted as specific, evolutionary designed interaction that targets a delicate and sensitive balance between protease and its inhibitor in healthy tissue.
Inactivation of host protease inhibitors by bacterial enzymes was described for SERPIN family members in numerous reports , where cleavage within the RSL, often at the P1-P19 peptide bond, leads to complete inactivation of the inhibitor. Inhibitors of the whey acidic protein family, including elafin and SLPI, are stable proteins and owing to their rigid core structure are often unsusceptible to proteolytic cleavage. So far, proteolysis was only reported for SLPI by RgpB (Into et al., 2006) and for elafin by dust mite proteases (Brown et al., 2003) , but these studies did not report the cleavage site.
Taken together, gingipains play an important role in modulating the balance between host proteases and their inhibitors at the infection site. The herein described distinctive inhibition of elafin by RgpB can add to the pathophysiology of gingivitis. Notably, elafin resisted inactivation by several S. aureus-derived serine and cysteine proteases confirming the high stability of this protein for proteolytic degradation. Therefore, we conclude that elafin inactivation by RgpB represents a specific pathogenic adaptation of P. gingivalis to disturb the protease-protease inhibitor balance in the infected gingival tissue. This leads to enhanced degradation of host proteins and generation of a pool of peptides serving as nutrients for this asaccharolytic pathogen.
Materials and methods
Materials
Reagents were obtained from Sigma-Aldrich (Taufkirchen, Germany) unless otherwise indicated. Enzymes included: human neutrophil elastase (HNE), EC 3.4.21.37 (Elastin Products, Owensville, MI, USA); staphopain A (ScpA) and staphopain B (SspB), MEROPS ID C47.001 and C47.002, respectively; glutamyl endopeptidase I (SspA), MEROPS ID S01.269; staphylococcal serine-protease-like A protease (SplA); gingipain R (HRgpA, RgpB), MEROPS ID C25.001, and gingipain K (Kgp), MEROPS ID C25.002. Elafin was provided by Proteo Biotech AG (Kiel, Germany).
The HNE active site was titrated with recombinant eglin C (Ciba Geigy, Basel, Switzerland). HNE proved to be more than 80% catalytically active. HNE was dissolved in 0.1 M sodium acetate (pH 5.0). Proteolytic activity was measured after each experiment by substrate assay with MeoSuc-Ala-Ala-Pro-Val-pnitroanilide as described below. Staphylococcal enzymes were purified according to procedures described in Drapeau (1978) , Potempa et al. (1988) , and Massimi et al. (2002) , and P. gingivalis proteases were obtained as described recently (Potempa and Nguyen, 2007) .
Elastase inhibition assays
For initial inactivation assays HNE was diluted in TET buffer -50 mM Tris-HCl, pH 7.6 containing 5 mM EDTA and 0.05% Tween-20 wstaphopain A, staphopain B, SplA, glutamyl endopeptidase I (V8 protease)x, or in TNCT buffer -0.2 M Tris-HCl, 0.15 M NaCl, 5 mM CaCl 2 , 0.05% Tween-20 (HRgpA, RgpB, Kgp). Cysteine proteinases were activated with 2 mM DTT in TET (ScpA, SspB) or with 10 mM L-cysteine in 0.2 M HEPES 5 mM CaCl 2 , pH 8.0 buffer (HRgpA, RgpB, Kgp) by 15 min incubation in 378C and further diluted in buffer specified above without reducing agents. Elafin was preincubated in the same buffer with a set of bacterial proteases at a concentration of 200 nM vs. 200 nM (1:1 molar ratio) for 2 h. Thereafter, the prepared solution of elastase was added to each sample and after 5 min the substrate MeoSuc-Ala-Ala-Pro-Val-pNa was added. The final mixture contained 25 nM HNE, 50 nM elafin, 50 nM respective bacterial enzyme and 1 mM substrate. The color development was monitored as p-nitroaniline release at 405 nm using microplate absorbance reader (Sunrise; TECAN Group Inc, Mä nnedorf, Switzerland). Concentration dependency was measured similarly using final concentrations of RgpB in the range of 0-10 nM, 10 nM elafin, and 5 nM elastase in a final volume of 200 ml.
SDS-PAGE
Electrophoresis was run in a Schagger/von Jagow tricine system using 15% acrylamide, with T/C 15.5:1 ratio (Schagger et al., 1988) . A total of 1 mg of elafin was applied per well. Protein size was indicated using the molecular marker SeeBlue Plus2 (Invitrogen, Hamburg, Germany). Protein bands were visualized using silver staining.
Western blot was performed by electrotransfer of proteins to PVDF membrane (Millipore, Schwalbach, Germany), followed by overnight blocking with 2% bovine albumin in Tris-buffered saline, 0.05% Tween-20 (TTBS). Blocked membrane was incubated for 1 h with primary antibody (1:500, biotinylated goat anti-human Trappin-2; BAF-1747; R&D, Wiesbaden-Nordenstadt, Germany), then washed 3 times with TTBS and streptavidin-HRP was applied for 1 h (1:20 000, RPN-1231; GE Healthcare, Munich, Germany). ECLq (GE Healthcare) was used as the chemiluminescence substrate and images were acquired using a Diana imager (Raytest, Straubenhardt, Germany).
High performance liquid chromatography (HPLC)
Preparations: A containing 10 mg of elafin and 100 nM activated RgpB in a total volume of 50 ml, B: 10 mg elafin, and C: 100 nM RgpB in TNCT buffer were incubated separately for 2 h at 378C. All samples were applied on the reverse-phase C2/C18 HPLC column mRPC SC 2.1/100 (GE Healthcare). The column was developed with an acetonitrile gradient using 0.1% TFA in H 2 O (solution A) and 80% acetonitrile in solution A (solution B) starting with 0% solution B changing to 25% after 10 min, 70% after 40 min, and 100% after 41 min. The fractions were collected automatically (SMART; Pharmacia, Uppsala, Sweden) and applied to mass spectrometry (see below). Identified peptides were tested for anti-elastase activity (see above) and were further reduced by incubation with 5 mM DTT at 378C for 1 h. After reduction, samples were rerun on the same HPLC column to separate resulting linearized peptides and gathered fractions were again analyzed using mass spectrometry. Protein concentrations of HPLC fractions were calculated from peak areas and a 5-fold molar excess of each fraction was used to test inhibitor activity as described above.
Reduction and alkylation
The fractions were lyophilized and the concentrations were adjusted to 4 mg of protein in 1 ml of ddH 2 O. The protein fractions (20 mg) were reduced in a mixture of 85 ml 100 mM NH 4 HCO 3 and 10 ml 100 mM DTT for 20 min at 658C. After reduction proteins were alkylated with 11 ml iodoacetamide for 20 min at ambient temperature in the dark. After reduction and alkylation the mixture was separated on an HPLC column (C2/ C18) as described above and analyzed by mass spectrometry.
Mass spectrometry
Protein and peptide mass determinations were performed by electrospray mass ionization spectrometry (ESI-MS) analyses using a Quadrupol time-of-flight Hybrid Mass spectrometer (Q-TOFீ II, Waters Micromass, Milford, MA, USA) equipped with an orthogonal electrospray source (Z-spray) operated in positive ionization mode. For MS analysis, 10 ml of HPLC fractions were lyophilized and diluted with 100 ml carrier solvent
